Table 4. Non-cardiac gene processes inhibited by Tbx5, Gata4 and Myocd.
Gene ontology name | T | G | M | T+G | G+M | T+M | T+G+M |
Non-cardiac | (permute P value) | ||||||
Embryonic limb morphogenesis | N | N | N | N | N | N | 0.017* |
Embryonic appendage morphogenesis | N | N | N | N | N | N | 0.017* |
Cartilage development | 0* | N | N | 0* | 0* | 0* | 0.001* |
Blood coagulation | 0.001* | 0* | 0.016* | 0.016* | 0.024* | N | 0.003* |
Tube morphogenesis | 0.077 | 0.049* | N | 0.06 | N | 0.006* | 0.006* |
Epidermis development | 0.062 | 0.002* | 0.013* | 0* | 0* | 0.006* | 0.008* |
Axonogenesis | 0.081 | 0.001* | 0* | 0.004* | 0.003* | 0* | 0.002* |
Ossification | 0.777 | 0.139 | 0.105 | 0.161 | 0.195 | 0.162 | 0.029* |
Central nervous system development | 0.055 | N | 0.189 | 0.398 | 0.152 | 0.026* | 0.013* |
Ectoderm development | 0.171 | 0.002* | 0.024* | 0.001* | 0* | 0.001* | 0.002* |
Embryonic development | 0.074 | 0.05 | 0.018* | 0.029* | 0.087 | 0.002* | 0.005* |
Neuron development | 0.417 | 0.006* | 0* | 0.034* | 0.021* | 0* | 0.011* |
Blood vessel development | 0.11 | 0.47 | 0.018* | 0.41 | 0.028* | 0.004* | 0.007* |
Skeletal development | 0.006* | 0* | 0* | N | 0* | 0* | 0* |
Development | 0* | 0* | 0* | 0* | 0* | 0* | 0* |
Humoral immune response | N | N | N | 0.563 | N | N | 0.011* |
Meiotic cell cycle | 0.521 | 0.007* | N | 0.008* | 0.007* | N | N |
Reproduction | 0.085 | 0.853 | 0.003* | 0.134 | 0.037* | 0.052 | 0.449 |
Germ cell development | 0.006* | N | 0.008* | N | N | N | N |
Eye development | 0.016* | N | 0.009* | 0.265 | N | N | N |
Gonad development | N | N | 0.012* | 0.065 | N | N | N |
T cell activation | 0.063 | 0.12 | 0.033* | 0.527 | 0.062 | 0.025* | 0.094 |
Female gamete generation | 0.002* | N | N | 0.058 | N | N | N |
GO terms with permute p<0.05 and a nested gene change number ≥4 were considered to be significantly inhibited. GOs with a nested gene change number <4 were shown as “N”. GO terms that were both activated and inhibited were excluded. T, Tbx5; G, Gata4; M, Myocd.